First-in-human study of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer: Update on safety and pharmacokinetics and initial report on pharmacodynamic responses and clinical benefit

被引：0
|
作者：
Camidge, D. R. [1 ]
Britten, C. D. [2 ]
Schellens, J. H. M. [3 ]
Guo, F. [4 ]
Milham, R. [4 ]
Eckhardt, S. G. [1 ]
Wong, S. G. [2 ]
Boss, D. S. [3 ]
Lucca, J. [5 ]
Jannes, P. A. [5 ]
机构：
[1] Univ Colorado, Denver, CO USA
[2] Univ Calif Los Angeles, Los Angeles, CA 90024 USA
[3] Netherlands Canc Inst, Amsterdam, Netherlands
[4] Pfizer Global Res & Dev, New London, CT USA
[5] Dana Farber Canc Inst, Boston, MA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3505S / 3505S
页数：1
相关论文
共 50 条
  • [21] A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
    Tolcher, Anthony
    Flaherty, Keith
    Shapiro, Geoffrey I.
    Berlin, Jordan
    Witzig, Thomas
    Habermann, Thomas
    Bullock, Andrea
    Rock, Edwin
    Elekes, Agnes
    Lin, Chester
    Kostic, Dusan
    Ohi, Naoto
    Rasco, Drew
    Papadopoulos, Kyriakos P.
    Patnaik, Amita
    Smith, Lon
    Cote, Gregory M.
    ONCOLOGIST, 2018, 23 (06): : 658 - +
  • [22] Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors
    Garrido-Laguna, Ignacio
    Dillon, Patrick M.
    Kabir, Sujan
    Mei, Jian
    Wade, Mark L.
    Yang, Huyuan
    Stapinski, Carl
    Foulks, Jason M.
    Warner, Steven L.
    Whatcott, Clifford
    Lebedinsky, Claudia
    Fu, Siqing
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [23] First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects
    Perera, Vidya
    Luettgen, Joseph M.
    Wang, Zhaoqing
    Frost, Charles E.
    Yones, Cynthia
    Russo, Cesare
    Lee, John
    Zhao, Yue
    LaCreta, Frank P.
    Ma, Xuewen
    Knabb, Robert M.
    Seiffert, Dietmar
    DeSouza, Mary
    Mugnier, Pierre
    Cirincione, Brenda
    Ueno, Takayo
    Frost, Robert J. A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (05) : 876 - 887
  • [24] Final results of a first-in-human clinical trial of OSI-027, a small molecule dual mTORC1/mTORC2 inhibitor in patients with advanced malignancies
    Schoffski, P.
    Mateo, J.
    Olmos, D.
    Barr, S.
    Poondru, S.
    Van Tornout, J.
    Dumez, H.
    LoRusso, P. M.
    Kaye, S. B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S162 - S163
  • [25] A first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma.
    Gounder, Mrinal M.
    Dickson, Mark Andrew
    Wu, Nian
    Ivy, S. Percy
    Carvajal, Richard D.
    D'Angelo, Sandra P.
    Keohan, Mary Louise
    Qin, Li-Xuan
    Erinjeri, Joseph Patrick
    Takebe, Naoko
    Tanner, Lanier
    Morales, Rita
    Condy, Mercedes M.
    Ustoyev, Yelena
    Maki, Robert G.
    Tap, William D.
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
    Cooper, A.
    Andelkovic, V.
    Wilkinson, K.
    Ganju, V.
    Lundy, J.
    Hong, M.
    Airey, S.
    Meng, L. L.
    Shen, B.
    Li, H.
    Yao, L.
    Zhang, M.
    Coward, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S487 - S487
  • [27] Interim results of a first-in-human, dose escalation and expansion study of PLB-1004, an irreversible inhibitor of exon 20 insertion mutations in patients with non-small cell lung cancer
    Yang, Jinji
    Wu, Yilong
    Huang, Meijuan
    Zhao, Yanqiu
    Zhao, Jun
    Zhou, Jianying
    Mao, Ying
    Wang, Huimin
    Fan, Yun
    Chung, David
    Schaab, Kevin
    CANCER RESEARCH, 2023, 83 (08)
  • [28] A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors.
    Calvert, Alan Hilary
    Gonzalez, Michael
    Ganguli, Sushila
    Ng, Matthew
    Benafif, Sarah
    Capelan, Marta
    Goldstein, Robert
    Shah, Krunal
    Jarvis, Claire
    Flynn, Michael
    Forster, Martin
    Anderson, Stephanie
    Schmitt-Hoffman, Anne
    Lane, Heidi
    Engelhardt, Marc
    Hannah, Alison L.
    Tzankov, Alexandar
    Bachmann, Felix
    Molife, L. Rhoda
    Kristeleit, Rebecca
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors
    Mahalingam, D.
    Wilding, G.
    Denmeade, S.
    Sarantopoulas, J.
    Cosgrove, D.
    Cetnar, J.
    Azad, N.
    Bruce, J.
    Kurman, M.
    Carducci, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 184 - 185
  • [30] First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.
    Di Giacomo, Anna Maria
    Santangelo, Federica
    Amato, Giovanni
    Simonetti, Elena
    Graham, Jill
    Lahn, Michael M. F.
    Van der Veen, Lars Anders
    Johnson, Zoe
    Pickering, Catherine Anne
    Durini, Marco
    Tan, Ziyang
    Tadepally, Lakshmikanth
    Brodin, Petter
    Occhipinti, Mariaelena
    Simonelli, Matteo
    Carlo-Stella, Carmelo
    Santoro, Armando
    Spiliopoulou, Pavlina
    Evans, T. R. Jeffry
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345